fda tirzepatide november 21 Eli Lilly Gets FDA Approval for Zepbound for Certain Sleep Apnea Patients

FDA has announced that the shortage of #tirzepatide, the ingredient in Lilly's Mounjaro and Zepbound, has been resolved. Compounding #pharmacies are required to cease production of compounded versions of tirzepatide within the

21.05

★★★★☆4.8 (126)

Lilly's Zepbound (aka tirzepatide) Lands FDA Approval for Weight Loss

29.39

★★★★★4.9 (98)

Friendly Reminder 💡 The only FDA‑approved U.S. brands of tirzepatide are Mounjaro and Zepbound. All tirzepatide available locally in the Philippines comes from the grey market. Even if tested in U.S. labs

29.75

★★★★★5.0 (157)

New Weight-Loss Drug Zeptbound Gets FDA Nod

27.57

★★★★★4.7 (84)

FDA says shortage of GLP-1 drug tirzepatide is over

27.78

★★★★★4.9 (203)

The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, Retatrutide

22.50

★★★★★5.0 (176)

FDA Approves Most Potent Weight Loss Drug Yet

28.28

★★★★★4.8 (132)